• Profile
Close

Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: A pooled analysis of randomized clinical trials

Advances in Therapy Aug 21, 2017

Ning G, et al. – The efficacy and safety of the dipeptidyl peptidase–4 inhibitor linagliptin were examined in Asian patients stratified by age, obesity, and renal function. Outcomes approved that linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled type 2 diabetes (T2D), irrespective of age, BMI, renal function, or ethnic subgroups, and was well tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay